{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:40:58Z","timestamp":1781278858526,"version":"3.54.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03328-y","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T14:02:10Z","timestamp":1724508130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disorders of hyperpigmentation and associated thyroid abnormalities: a retrospective cohort study"],"prefix":"10.1007","volume":"316","author":[{"given":"Sarah","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle Carolina","family":"Mora Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Syder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Quarshie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raveena","family":"Ghanshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Rodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Elbuluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"key":"3328_CR1","doi-asserted-by":"crossref","unstructured":"Rostami Mogaddam M, Iranparvar Alamdari M, Maleki N, Safavi Ardabili N, Abedkouhi S. Evaluation of autoimmune thyroid disease in melasma. J Cosmet Dermatol. Jun 2015;14(2):167\u2009\u2212\u200971. doi:10.1111\/jocd.12138","DOI":"10.1111\/jocd.12138"},{"key":"3328_CR2","doi-asserted-by":"crossref","unstructured":"Kheradmand M, Afshari M, Damiani G, Abediankenari S, Moosazadeh M. Melasma and thyroid disorders: a systematic review and meta-analysis. Int J Dermatol 2019;58(11):1231\u20131238. doi:10.1111\/ijd.14497","DOI":"10.1111\/ijd.14497"},{"key":"3328_CR3","unstructured":"Karn D, Kc S, Timalsina M. Lichen Planus Pigmentosus: A study for association of Thyroid Dysfunction. Kathmandu Univ Med J 2016;14(53):36\u201340. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27892439\/"},{"key":"3328_CR4","doi-asserted-by":"crossref","unstructured":"Atefi N, Behrangi E, Nasiripour S, et al. A double blind randomized trial of efficacy and safety of 5% methimazole versus 2% hydroquinone in patients with melasma. Journal of Skin and Stem Cell. 2017;4(2). https:\/\/doi.org\/10.5812\/jssc.62113","DOI":"10.5812\/jssc.62113"},{"key":"3328_CR5","doi-asserted-by":"crossref","unstructured":"Malek J, Chedraoui A, Nikolic D, Barouti N, Ghosn S, Abbas O. Successful treatment of hydroquinone-resistant melasma using topical methimazole. Dermatol Ther. Jan-Feb 2013;26(1):69\u201372. doi:10.1111\/j.1529-8019.2012.01540.x","DOI":"10.1111\/j.1529-8019.2012.01540.x"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03328-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03328-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:09:31Z","timestamp":1729699771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03328-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":5,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03328-y","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Elbuluk has served as a consultant, advisory board member, and\/or speaker for Avita, Scientis, Incyte, VisualDx, Beiersdorf, Unilever, Eli Lilly, Galderma, Pfizer, La Roche Posay, L\u2019Oreal, McGraw Hill, Dior, Medscape, Abbvie, Takeda, Sanofi. She has received royalties from McGraw-Hill. She has stock options in VisualDx. The remaining authors have no disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Exempt review determined by the University of Southern California (USC) Institutional Review Board (IRB) Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB approval status"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"572"}}